Teva Gets Price Target Lift to $38 After $500M Phase 3 Boost, Faces $300M Generics Hit
Truist raised Teva’s price target to $38 from $36 after Q4 results included a one-time $500 million Duvakitug Phase 3 payment, while projecting $300 million generics sales loss in Q1 2026. Zacks upgrade to a Buy rating reflects optimism on Teva’s early-stage pipeline and potential late-2026 FDA ruling on Olanzapine LAI.
1. Price Target Upgrade
Truist boosted Teva’s price target by 5.6% to $38 from $36, maintaining a Buy rating based on the company’s Q4 performance. The firm highlighted inventory loading effects and the Inflation Reduction Act’s challenges for comparisons in 2026.
2. Duvakitug Payment and Generics Headwind
Teva’s Q4 results included a one-time $500 million payment linked to its Duvakitug Phase 3 trial, which provided a near-term earnings boost. However, the generics division faces an estimated $300 million sales decline in Q1 2026 due to the loss of gRevlimid exclusivity.
3. Pipeline Prospects and FDA Decision
Several late-stage assets underpin growth expectations, including a potential FDA decision on Olanzapine LAI in late 2026. Analysts project this long-acting schizophrenia therapy could generate peak sales near $3 billion, supporting early-stage pipeline optimism.